June 1, 2021 07:03 AM EDTUpdated 10:08 AM

Novartis scraps a slate of Beovu trials after 4-week dosing turned up safety issues — dashing hopes of dethroning Eylea

Safety concerns have forced Novartis to slam the brakes on a trio of late-stage clinical studies for its eye drug Beovu, marring grand ambitions to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis scraps a slate of Beovu tri­als af­ter 4-week dos­ing turned up safe­ty is­sues — dash­ing hopes of de­thron­ing Eylea